📰 Human Use News

Page 135 - Human Use News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.

Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17

June 23, 2022

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...

United States Stanleyc Erck Ali Chartan Department Of Defense National Institute Of Allergy European Union

Source: prnewswire.com

Why Novavax Stock Is Soaring This Week

June 23, 2022

The company's COVID-19 vaccine could soon be available to adolescents in the European Union.

European Union European Commission Drug Administration European Medicines Agency Medicinal Products Human Use

Source: fool.com

Novartis receives European Commission approval for Tabrecta® for the treatment of METex14 skipping advanced non-small cell lung cancer | Small Molecules

June 22, 2022

Novartis receives European Commission approval for Tabrecta® for the treatment of METex14 skipping advanced non-small cell lung cancer

United States Juergen Wolf World Health Organization European Commission University Hospital Cologne Innovative Medicines International

Source: pipelinereview.com

Daiichi Sankyo: Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

June 22, 2022

Application based on DESTINY-Breast04 results that showed Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan demonstrated superior progression-free and overall survival versus chemotherapy Daiichi

United States Masashi Kawase Daiichi Sankyo Daiichi Sankyo Europe Gmb Trastuzumab Deruxtecan Simone Jendsch Dow

Source: finanznachrichten.de

Merck Wins Key FDA Approval for Pediatric Pneumococcal Vaccine

June 22, 2022

On Wednesday, the FDA approved Merck's pneumococcal 15-valent conjugate vaccine for children 6 weeks through 17 years of age.

Steven Shapiro Eliav Barr Chris Hondros Getty Us Centers For Disease Merck Research Laboratories European Commission

Source: biospace.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Global Therapeutic Proteins Market Report 2022-2031 Featuring Major Players - Abbott Laboratories; Amgen Inc.; Baxter International Inc.; Eli Lilly and Company; F.Hoffmann-La Roche

June 20, 2022

/PRNewswire/ -- The "Therapeutic Proteins Global Market Report 2022: By Product, By Application, By Function" report has been added to ResearchAndMarkets.coms...

United States Merck Serono Samsung Bioepis Eli Lilly Laura Wood Novo Nordisk

Source: prnewswire.com

Global Therapeutic Proteins Market Analysis Report 2022: A

June 20, 2022

Dublin, June 20, 2022 (GLOBE NEWSWIRE) -- The "Therapeutic Proteins Global Market Report 2022: By Product, By Application, By Function" report has been...

United States Merck Serono Samsung Bioepis Eli Lilly Novo Nordisk Baxter International

Source: globenewswire.com

ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

June 18, 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United States Shauna Dillon Katja Buhrer Exchange Commission European Commission Drug Administration

Source: apnews.com

ObsEva SA: ObsEva Announces European Commission Marketing Authorization for Yselty (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

June 17, 2022

-Yselty (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty; ObsEva

United States Shauna Dillon Katja Buhrer Exchange Commission European Commission Drug Administration

Source: finanznachrichten.de